Cargando…

Synthesis, crystal structure, DFT, Hirshfeld surface analysis, energy frameworks and in-Silico drug-targeting PFKFB3 kinase of novel triazolequinoxalin derivative (TZQ) as a therapeutic Strategy against cancer

Overall, drug design is a dynamic and evolving field, with researchers constantly working to improve their understanding of molecular interactions, develop new computational methods, and explore innovative techniques for creating effective and safe medications. The process can involve steps such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Abad, Nadeem, Al-Ostoot, Fares Hezam, Ashraf, Sajda, Chkirate, Karim, Aljohani, Majed S., Alharbi, Hussam Y., Buhlak, Shafeek, El Hafi, Mohamed, Van Meervelt, Luc, Al-Maswari, Basheer M., Essassi, El Mokhtar, Ramli, Youssef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618769/
https://www.ncbi.nlm.nih.gov/pubmed/37920528
http://dx.doi.org/10.1016/j.heliyon.2023.e21312
_version_ 1785129848213078016
author Abad, Nadeem
Al-Ostoot, Fares Hezam
Ashraf, Sajda
Chkirate, Karim
Aljohani, Majed S.
Alharbi, Hussam Y.
Buhlak, Shafeek
El Hafi, Mohamed
Van Meervelt, Luc
Al-Maswari, Basheer M.
Essassi, El Mokhtar
Ramli, Youssef
author_facet Abad, Nadeem
Al-Ostoot, Fares Hezam
Ashraf, Sajda
Chkirate, Karim
Aljohani, Majed S.
Alharbi, Hussam Y.
Buhlak, Shafeek
El Hafi, Mohamed
Van Meervelt, Luc
Al-Maswari, Basheer M.
Essassi, El Mokhtar
Ramli, Youssef
author_sort Abad, Nadeem
collection PubMed
description Overall, drug design is a dynamic and evolving field, with researchers constantly working to improve their understanding of molecular interactions, develop new computational methods, and explore innovative techniques for creating effective and safe medications. The process can involve steps such as the identification of targets, the discovery of lead compounds, lead optimization, preliminary testing, human trials, regulatory approval and finally post-marketing surveillance, all aimed at bringing a new drug from concept to market. In this article, the synthesis of the novel triazolequinoxalin (TZQ) 1-((1-hexyl-1H-1,2,3-triazol-5-yl)methyl)-3-phenylquinoxalin-2(1H)-one (4) is reported. The structure has been identified with a variety of spectroscopic methods (1H, 13C NMR, and LC-MS) and finally, the structure has been determined by X-ray diffraction (XRD) studies. The TZQ molecule has crystallized in the monoclinic space C2/c group with unit cell dimensions a = 41.201(2) Å, b = 10.6339(6) Å, c = 9.4997(4) Å, β = 93.904(4). The crystal structure is stabilized by intermolecular interactions (N–H ⋯ O and N–H … Cg) occurring within the molecule. The presence of these intermolecular interactions is evaluated through analysis of Hirshfeld surfaces (HS) and two-dimensional (2D) chemical fingerprints map. Additionally, energy frameworks were employed to identify the prevailing interaction energy influencing the molecular arrangement. Density Functional Theory (DFT) calculations were computed to establish concurrence between theoretical and experimental results. Furthermore, the HOMO-LUMO energy levels were determined using the B3LYP/6-31+G(d, p) level of theory. Finally, molecular docking was used to predict the anti-cancer activity of the compound (4) against PFKFB3 kinase and presented noticeable hydrophilic and hydrophobic interactions at the active site region.
format Online
Article
Text
id pubmed-10618769
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106187692023-11-02 Synthesis, crystal structure, DFT, Hirshfeld surface analysis, energy frameworks and in-Silico drug-targeting PFKFB3 kinase of novel triazolequinoxalin derivative (TZQ) as a therapeutic Strategy against cancer Abad, Nadeem Al-Ostoot, Fares Hezam Ashraf, Sajda Chkirate, Karim Aljohani, Majed S. Alharbi, Hussam Y. Buhlak, Shafeek El Hafi, Mohamed Van Meervelt, Luc Al-Maswari, Basheer M. Essassi, El Mokhtar Ramli, Youssef Heliyon Research Article Overall, drug design is a dynamic and evolving field, with researchers constantly working to improve their understanding of molecular interactions, develop new computational methods, and explore innovative techniques for creating effective and safe medications. The process can involve steps such as the identification of targets, the discovery of lead compounds, lead optimization, preliminary testing, human trials, regulatory approval and finally post-marketing surveillance, all aimed at bringing a new drug from concept to market. In this article, the synthesis of the novel triazolequinoxalin (TZQ) 1-((1-hexyl-1H-1,2,3-triazol-5-yl)methyl)-3-phenylquinoxalin-2(1H)-one (4) is reported. The structure has been identified with a variety of spectroscopic methods (1H, 13C NMR, and LC-MS) and finally, the structure has been determined by X-ray diffraction (XRD) studies. The TZQ molecule has crystallized in the monoclinic space C2/c group with unit cell dimensions a = 41.201(2) Å, b = 10.6339(6) Å, c = 9.4997(4) Å, β = 93.904(4). The crystal structure is stabilized by intermolecular interactions (N–H ⋯ O and N–H … Cg) occurring within the molecule. The presence of these intermolecular interactions is evaluated through analysis of Hirshfeld surfaces (HS) and two-dimensional (2D) chemical fingerprints map. Additionally, energy frameworks were employed to identify the prevailing interaction energy influencing the molecular arrangement. Density Functional Theory (DFT) calculations were computed to establish concurrence between theoretical and experimental results. Furthermore, the HOMO-LUMO energy levels were determined using the B3LYP/6-31+G(d, p) level of theory. Finally, molecular docking was used to predict the anti-cancer activity of the compound (4) against PFKFB3 kinase and presented noticeable hydrophilic and hydrophobic interactions at the active site region. Elsevier 2023-10-20 /pmc/articles/PMC10618769/ /pubmed/37920528 http://dx.doi.org/10.1016/j.heliyon.2023.e21312 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Abad, Nadeem
Al-Ostoot, Fares Hezam
Ashraf, Sajda
Chkirate, Karim
Aljohani, Majed S.
Alharbi, Hussam Y.
Buhlak, Shafeek
El Hafi, Mohamed
Van Meervelt, Luc
Al-Maswari, Basheer M.
Essassi, El Mokhtar
Ramli, Youssef
Synthesis, crystal structure, DFT, Hirshfeld surface analysis, energy frameworks and in-Silico drug-targeting PFKFB3 kinase of novel triazolequinoxalin derivative (TZQ) as a therapeutic Strategy against cancer
title Synthesis, crystal structure, DFT, Hirshfeld surface analysis, energy frameworks and in-Silico drug-targeting PFKFB3 kinase of novel triazolequinoxalin derivative (TZQ) as a therapeutic Strategy against cancer
title_full Synthesis, crystal structure, DFT, Hirshfeld surface analysis, energy frameworks and in-Silico drug-targeting PFKFB3 kinase of novel triazolequinoxalin derivative (TZQ) as a therapeutic Strategy against cancer
title_fullStr Synthesis, crystal structure, DFT, Hirshfeld surface analysis, energy frameworks and in-Silico drug-targeting PFKFB3 kinase of novel triazolequinoxalin derivative (TZQ) as a therapeutic Strategy against cancer
title_full_unstemmed Synthesis, crystal structure, DFT, Hirshfeld surface analysis, energy frameworks and in-Silico drug-targeting PFKFB3 kinase of novel triazolequinoxalin derivative (TZQ) as a therapeutic Strategy against cancer
title_short Synthesis, crystal structure, DFT, Hirshfeld surface analysis, energy frameworks and in-Silico drug-targeting PFKFB3 kinase of novel triazolequinoxalin derivative (TZQ) as a therapeutic Strategy against cancer
title_sort synthesis, crystal structure, dft, hirshfeld surface analysis, energy frameworks and in-silico drug-targeting pfkfb3 kinase of novel triazolequinoxalin derivative (tzq) as a therapeutic strategy against cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618769/
https://www.ncbi.nlm.nih.gov/pubmed/37920528
http://dx.doi.org/10.1016/j.heliyon.2023.e21312
work_keys_str_mv AT abadnadeem synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT alostootfareshezam synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT ashrafsajda synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT chkiratekarim synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT aljohanimajeds synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT alharbihussamy synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT buhlakshafeek synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT elhafimohamed synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT vanmeerveltluc synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT almaswaribasheerm synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT essassielmokhtar synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer
AT ramliyoussef synthesiscrystalstructuredfthirshfeldsurfaceanalysisenergyframeworksandinsilicodrugtargetingpfkfb3kinaseofnoveltriazolequinoxalinderivativetzqasatherapeuticstrategyagainstcancer